参一胶囊联合GP化疗方案治疗非小细胞肺癌的疗效分析  

Shenyi Capsule Combined with GP Regimen in the Treatment of Non-small Cell Lung Cancer Clinical Analysis

作　　者：李远航[1] 白维君[1] 

机构地区：[1]中国医科大学肿瘤医院肿瘤内科,辽宁沈阳110001

出　　处：《辽宁中医杂志》2017年第3期553-555,共3页Liaoning Journal of Traditional Chinese Medicine

摘　　要：目的:对于非小细胞肺癌患者,文章旨再比较GP化疗联合中药参一胶囊的疗效及不良反应。方法:本组病例共计180例,其中A组90例,应用化疗联合参一胶囊治疗;B组90例,应用单纯化疗治疗。两组患者均以3周为1个治疗周期,疗效及不良反应评价则选取治疗后两个周期时的结果予以判定。结果:180例患者均可评价疗效。其中,A组疾病控制率(DCR)为91.11%,中位无进展生存期(PFS)为4.1个月,B组DCR为35.56%,中位PFS为3.1个月,两组比较差异有统计学意义(P=0.045,P=0.05)。B组血小板降低发生率高于A组(75.55%vs 10%),两组不良反应的差异具有统计学意义(P<0.05)。A组客观反应率(ORR)为22.22%,B组ORR为11.11%,两组比较差异无统计学意义(P=0.876)。结论:应用参一胶囊联合GP化疗方案治疗非小细胞肺癌,可以提高临床有效率,降低不良反应的发生。Objective： In patients with small cell lung cancer,the purpose of this paper is to compare the effect and adverse reaction of GP chemotherapy combined with Shenyi capsule. Methods： In accordance with into the standard group of 81 patients and40 cases received chemotherapy combined with Shenyi capsule（ group A）,41 cases received chemotherapy alone（ group B）,21 days for a cycle,at least 2 cycles of chemotherapy in patients with curative effect and adverse reactions were evaluated. Results：There were 81 patients assessable for efficacy,which a set of objective response rate（ ORR） was 22. 22%. In group B,Orr was11. 11%. The difference between the two groups was not significant P = 0. 876; the diseases control rate（ DCR） was 91. 11%,the median progression free survival（ PFS） was 4. 1 months. Group B DCR was 35. 56%,the median PFS was 3. 1 months. The difference between the two groups had statistical significance（ P = 0. 045,P = 0. 05）. B group rash rate was higher than group A（ 75. 55% vs 10%）. Differences in adverse reactions of the two groups were statistically significant（ P〈0. 05）. Conclusion： Application of Shenyi capsule combined with GP chemotherapy regimen in the treatment of small cell lung cancer can improve clinical efficiency and reduce the occurrence of adverse reactions.

关 键 词：非小细胞肺癌 参一胶囊 GP化疗方案 

分 类 号：R734.2[医药卫生—肿瘤]